Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 226

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 226
---
, the Company reported
an accumulated deficit of $13,703.

To support
its operations and advance its development programs, the Company intends to continue securing investments from qualified investors. Management
anticipates that additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring
healthcare or healthcare-related technologies. However, there are currently no binding commitments for further investment, and there
can be no assurance that the Company will secure the required capital on commercially reasonable terms, or at all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management believes that the Company’s existing financial resources will
be sufficient to sustain its planned operations for at least the next twelve months.

<div align='center'>F-40</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 1: - GENERAL (Cont.)

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

These unaudited condensed consolidated
financial statements should be read in conjunction with the consolidated financial statements and accompanying notes for the year ended
December 31, 2024. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2024,
are applied consistently in these interim consolidated financial statements.

Following the closing on July 23,
2024 of the Share Exchange Agreement with Lipovation Ltd. whereby Lipovation Ltd. become a wholly owned subsidiary of Revium Rx, in accordance
with ASC 810, Lipovation’s financial statement are presented as the “Predecessor” for periods prior to the closing
of the acquisition. Revium Rx, which includes consolidation of Lipovation Ltd. subsequent to the acquisition, is the “Successor”
for periods after the closing of the acquisition. As a result of the application of the acquisition method of accounting in the Successor
period, the financial statements for the Successor period are presented on a full step-up basis as a result of the acquisition and are
therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis.

Recently Issued Accounting Pronouncements not yet adopted

In December 2023, the FASB issued
ASU 2023-09, Income Taxes (Topic 740), Improvements to